rsv
bronchiol
hospitalis
u
r
last
year
studi
determin
predisposit
sever
bronchiol
consequ
studi
highlight
variou
singlenucleotid
polymorph
snp
significantli
associ
respiratori
syncyti
viru
rsv
hospitalis
candid
gene
approach
demonstr
innat
immun
gene
snp
strongest
associ
bronchiol
impact
virus
rsv
influenza
adenoviru
parainfluenza
rhinoviru
human
metapneumoviru
hmpv
coronaviru
bocaviru
enteroviru
paraechoviru
investig
one
seri
children
rsv
infect
experienc
recurr
wheez
anoth
rsv
infect
associ
respiratori
complic
hypoxia
correl
prolong
hospitalis
other
examin
longterm
outcom
viral
infect
infanc
studi
other
publish
last
year
discuss
past
year
signific
number
studi
determin
predisposit
sever
bronchiol
consequ
one
studi
examin
hospitalis
rsv
twin
born
denmark
total
infant
concord
rsv
infect
greater
ident
fratern
twin
rate
versu
respect
suggest
genet
link
suscept
sever
rsv
infect
influenc
genet
factor
famili
environ
nonshar
environ
studi
highlight
variou
singlenucleotid
polymorph
significantli
associ
rsv
hospitalis
result
alway
consist
rsv
fusion
protein
activ
cell
tolllik
receptor
tlr
tlr
polymorph
encod
associ
tlr
hyporespons
increas
suscept
bacteri
infect
studi
evalu
dna
sampl
highrisk
patient
heterozygos
singl
nucleotid
polymorph
associ
symptomat
rsv
diseas
p
contrast
anoth
studi
children
rsv
infect
healthi
control
polymorph
associ
risk
sever
rsv
infect
impact
proinflammatori
cytokin
product
interleukin
il
induc
interferongamma
product
inhibit
immunoglobulin
e
ige
product
polymorph
associ
elev
serum
ige
level
atopi
asthma
studi
children
sever
rsv
infect
control
polymorph
associ
sever
rsv
infect
haplotyp
analys
reveal
associ
six
polymorph
evalu
studi
p
sever
rsv
infect
also
associ
enhanc
chemokin
includ
rant
activ
increas
epitheli
cell
nasal
secret
children
rsv
children
hospitalis
rsv
infect
sexmatch
healthi
adult
rant
promot
gene
polymorph
combin
genotyp
common
case
rsv
hospitalis
control
candid
gene
investig
studi
children
hospitalis
rsv
bronchiol
parent
random
popul
control
singl
nucleotid
polymorph
strongest
associ
bronchiol
includ
vitamin
receptor
vdr
jun
oncogen
encod
transcript
factor
activ
essenti
cell
cycl
progress
dna
replic
interferon
alpha
nitric
oxid
synthas
figur
studi
also
evalu
genet
suscept
viral
infect
one
studi
occurr
tlr
polymorph
compar
infant
six
month
age
hospitalis
bronchiol
unselect
blood
donor
regard
proport
polymorph
infant
rsv
bronchiol
differ
control
wherea
nonrsv
bronchiol
like
allel
g
polymorph
compar
control
p
effect
genet
polymorph
late
wheez
follow
rsv
infect
studi
children
hospitalis
rsv
lower
respiratori
tract
infect
follow
six
year
parent
kept
daili
log
regist
respiratori
symptom
first
three
year
followup
six
year
gln
allel
associ
late
wheez
odd
ratio
earli
wheez
studi
suggest
differ
children
develop
earli
versu
late
wheez
mani
year
clinician
reli
nasal
pharyng
aspir
diagnos
rsv
new
techniqu
includ
polymeras
chain
reaction
pcr
diagnosi
could
made
utilis
saliva
throat
swab
readili
access
nasal
pharyng
aspir
lower
viral
load
recent
studi
howev
compar
yield
posit
nasal
pharyng
aspir
throat
swab
saliva
specimen
children
less
year
age
reveal
throat
swab
saliva
specimen
less
sensit
nasal
pharyng
aspir
virus
detect
nasal
pharyng
aspir
throat
swab
saliva
specimen
detect
virus
respect
rapid
antigen
detect
assay
becom
import
tool
diagnosi
rsv
conjunct
convent
diagnost
method
may
facilit
prompt
treatment
infect
patient
result
gener
avail
use
chromatograph
immunoassay
cia
within
minut
direct
fluoresc
antibodi
dfa
detect
within
two
hour
four
rapid
antigen
detect
assay
rsv
includ
rapid
chromatograph
immunoassay
cia
direct
fluoresc
antibodi
dfa
assay
two
dfa
assay
human
metapneumoviru
hmpv
prospect
evalu
compar
nasopharyng
aspir
result
realtim
revers
transcriptas
rt
pcr
cia
poor
sensit
rsv
specif
turnaround
time
minut
although
rsv
dfa
sensit
specif
turnaround
time
minut
highli
demand
technic
time
expertis
hmpv
dfa
assay
poor
sensit
turnaround
time
minut
base
result
rapid
antigen
test
requir
improv
routin
use
clinic
practic
multiplex
pcr
allow
detect
number
virus
one
specimen
infant
less
month
age
hospitalis
first
wheez
episod
viral
infect
determin
nasopharyng
aspir
use
multiplex
pcr
detect
rsv
influenza
adenoviru
parainfluenza
rhinoviru
rv
hmpv
coronaviru
bocaviru
enteroviru
paraechoviru
rsv
frequent
detect
pathogen
children
infect
rsv
experienc
recurr
wheez
defin
new
episod
wheez
month
follow
initi
episod
viral
load
higher
recurr
wheez
asthma
multicent
infant
cohort
studi
investig
incid
etiolog
lower
respiratori
tract
infect
home
visit
viral
test
infant
less
one
year
age
incid
rate
least
one
lower
respiratori
tract
infect
personyear
rsv
frequent
isol
pathogen
risk
lower
respiratori
tract
infect
higher
infant
matern
histori
asthma
sibl
risk
infect
lower
infant
breast
fed
week
lower
socioeconom
class
prospect
twoyear
studi
singl
coinfect
hospitalis
infant
nasopharyng
aspir
posit
infect
molecular
detect
use
identifi
pathogen
genotyp
viral
strain
conduct
sequenc
analysi
infect
infant
posit
rsv
rsva
posit
hmpv
bocaviru
coronaviru
coinfect
rate
high
rsv
hmpv
bocaviru
coronaviru
rsv
associ
respiratori
complic
bacteri
pneumonia
hypoxia
hypoxia
correl
prolong
hospitalis
studi
monoinfect
rsv
compar
rsvhmpv
coinfect
result
longer
hospitalis
wors
hypoxia
p
unfortun
recent
studi
manag
rsv
infect
prospect
studi
evalu
efficaci
nasal
continu
posit
airway
pressur
cpap
respiratori
distress
symptom
respiratori
effort
infant
less
three
month
age
rsvposit
bronchiol
patient
paediatr
intens
care
unit
picu
pco
greater
mmhg
clinic
score
greater
oesophag
pressur
measur
use
determin
pressur
time
product
measur
work
breath
pressur
time
product
decreas
significantli
one
hour
six
hour
cpap
baselin
pressur
time
product
mean
se
cmh
osmin
one
hour
post
cpap
p
hour
post
cpap
pressur
time
product
p
infant
requir
intub
averag
length
stay
picu
seven
day
find
suggest
cpap
may
use
infant
bronchiol
need
test
randomis
trial
retrospect
review
efficaci
high
frequenc
oscillatori
ventil
hfov
evalu
six
infant
rsv
bronchiol
hypercapn
respiratori
failur
overexpand
lung
pattern
chest
radiograph
acut
respiratori
distress
syndrom
ard
use
hfov
associ
improv
oxygen
increas
mean
airway
pressur
mean
cmh
cmh
fall
paco
mmhg
infant
extub
cpap
supplementari
oxygen
within
hour
treatment
signific
complic
due
treatment
hfov
infant
requir
adrenerg
support
renal
function
affect
although
randomis
control
clinic
trial
data
suggest
rsvinduc
respiratori
failur
hypercapnia
infant
might
respond
hfov
children
hospitalis
rsv
treat
antibiot
yet
secondari
bacteri
infect
occur
less
patient
recent
multicentr
doubleblind
equival
studi
dutch
antibiot
rsv
trial
dart
research
group
evalu
whether
antibiot
would
reduc
durat
hospitalis
patient
rsv
azithromycin
mgkgday
placebo
administ
infant
less
month
age
diagnosi
rsv
infant
randomis
three
year
studi
period
studi
termin
due
lack
differ
durat
hospitalis
azithromycin
group
hour
placebo
group
hour
failur
azithromycin
resolv
clinic
symptom
quickli
suggest
infant
children
rsv
infect
benefit
treatment
antibiot
impact
ribavirin
risk
asthma
allerg
sensitis
evalu
hospitalis
children
less
two
year
age
rsv
infect
wheez
determin
clinician
questionnair
ribavirin
administ
children
persist
respiratori
distress
deterior
cyanosi
respiratori
failur
followup
cumul
asthma
significantli
reduc
children
receiv
ribavirin
compar
control
likewis
current
symptom
asthma
wheez
significantli
reduc
patient
receiv
ribavirin
compar
control
studi
howev
randomis
followup
therefor
result
interpret
caution
impact
ribavirin
children
rsv
remain
inconclus
prematur
birth
chronic
lung
diseas
prematur
infant
immunodefici
associ
higher
morbid
mortal
rate
children
rsv
german
dm
rsv
ped
databas
provid
prospect
multicentr
document
rsv
hospitalis
paediatr
centr
six
rsv
season
databas
interrog
provid
confirm
increas
risk
sever
rsv
diseas
prematur
infant
particularli
chronic
lung
diseas
treat
within
last
six
month
prior
infect
analysi
databas
show
rsv
infect
prematur
infant
mortal
prematur
born
infant
bpd
prematur
born
infant
infant
born
full
term
prematur
birth
chronic
lung
diseas
treatment
within
last
six
month
nosocomi
infect
significantli
associ
complic
cours
diseas
includ
pneumonia
apnoeabradycardia
supplementari
oxygen
picu
admiss
base
result
analysi
investig
conclud
current
nation
guidelin
prophylaxi
appropri
patient
popul
anoth
studi
conduct
identifi
risk
factor
rsv
compar
caus
lower
respiratori
tract
infect
rural
birth
cohort
kenyan
children
children
monitor
acut
respiratori
infect
three
rsv
epidem
rsv
diagnos
immunofluoresc
assay
nasal
wash
acut
respiratori
infect
episod
four
hundr
sixtynin
children
experienc
lower
respiratori
tract
infect
rsv
lower
respiratori
tract
infect
associ
sever
stunt
overcrowd
number
sibl
six
year
age
higher
educ
level
primari
caretak
protect
infect
populationbas
studi
demonstr
tempor
relationship
rsv
infect
invas
pneumococc
diseas
prospect
populationbas
cohort
studi
use
registri
inform
hospitalis
denmark
conduct
investig
relationship
rsv
infect
invas
pneumococc
diseas
registri
includ
rsv
hospitalis
case
invas
pneumococc
diseas
children
less
two
year
age
hospitalis
rsv
increas
risk
invas
pneumococc
diseas
day
hospitalis
rate
ratio
investig
propos
mechan
associ
direct
damag
viru
result
secondari
bacteri
infect
atopi
earli
life
viral
infect
identifi
independ
risk
factor
develop
asthma
communitybas
cohort
studi
children
high
risk
atopi
figur
studi
episod
acut
respiratori
ill
captur
first
year
aspir
obtain
viral
identif
wheez
asthma
evalu
six
month
two
five
year
studi
asthma
defin
doctor
diagnosi
asthma
ever
year
current
asthma
includ
presenc
asthma
wheez
prior
followup
visit
wheez
defin
highpitch
whistl
sound
come
chest
expir
transient
wheez
includ
wheez
episod
first
year
life
lateonset
wheez
defin
wheez
year
age
wheez
occur
year
persist
wheez
defin
wheez
year
studi
current
wheez
defin
wheez
month
prior
followup
visit
analysi
aspir
reveal
episod
due
virus
rsv
rv
five
year
children
current
wheez
risk
factor
develop
asthma
identifi
wheezi
infect
andor
febril
lower
respiratori
tract
infect
infant
especi
caus
rsv
rv
infect
importantli
risk
factor
correl
asthma
children
sensitis
two
year
age
demonstr
interact
earli
life
viral
infect
atopi
causat
asthma
atop
children
n
age
month
hospitalis
within
first
two
year
wheez
acut
respiratori
tract
infect
follow
median
age
year
lung
function
measur
figur
twentyfour
children
rsv
infect
viral
infect
determin
antigen
detect
nasopharyng
aspir
obtain
hospitalis
antibodi
determin
pair
sera
rsv
also
assess
rt
pcr
frozen
nasopharyng
aspir
lung
function
measur
reveal
children
rsv
infect
compar
without
approxim
year
prior
measur
evid
follow
restrict
abnorm
children
rsv
posit
fvc
predict
compar
children
rsv
neg
forc
expiratori
volum
one
second
fev
fvc
children
rsv
posit
neg
respect
multivari
model
decreas
fvc
essenti
normal
fev
valu
suggest
rsv
independ
predictor
lower
fvc
rsv
bronchiol
associ
perman
abnorm
restrict
pattern
lung
function
past
year
numer
public
further
understand
genet
predisposit
rsv
although
data
requir
care
consider
regard
sampl
size
type
popul
risk
factor
signific
long
term
airway
morbid
follow
viral
lower
respiratori
tract
infect
role
atopi
premorbid
abnorm
lung
function
requir
clarif
multicentr
randomis
clinic
trial
need
inform
manag
author
conflict
interest
fund
sourc
sixth
global
expert
meet
develop
meet
proceed
provid
abbott
